NeuroSpectra Bridge creates the first true bidirectional communication platform between biological neural networks (SNN organoids) and artificial neural networks (CTMs).
Our proprietary platform combines cutting-edge neuroscience with advanced machine learning to create a seamless interface between biological and artificial intelligence.
Our technology enables real-time communication between Spiking Neural Networks (biological neurons) and Artificial Neural Networks, creating a hybrid intelligence system.
Proprietary electrode arrays and signal processing algorithms capture neural activity with unprecedented spatial and temporal resolution.
Our system continuously adapts to the unique electrophysiological signatures of each neural network, optimizing the interface over time.
The world's first complete system for creating, monitoring, and interfacing with hybrid biological-artificial neural networks.
Precision-controlled environment for cultivating and maintaining healthy SNN organoids with optimal growth conditions.
1024-channel high-density electrode array combined with optical sensors for comprehensive neural activity monitoring.
Converts between spiking neural patterns and artificial neural network activations with sub-millisecond latency.
Precise electrical and optogenetic stimulation capabilities for bidirectional communication with neural networks.
NeuroSpectra Bridge opens new frontiers in neuroscience, medicine, and artificial intelligence research.
Create accurate models of neurological disorders using patient-derived organoids for drug discovery and personalized medicine.
Develop next-generation AI that combines the efficiency of silicon with the adaptability and energy efficiency of biological neurons.
Create brain-computer interfaces that integrate seamlessly with the nervous system for restoring lost sensory or motor functions.
Test drug effects on human neural networks without animal testing, accelerating development of neuroactive compounds.
Study the neural basis of learning, memory, and decision-making in controlled human neural network environments.
Develop direct communication pathways between the brain and external devices for assistive technologies and beyond.
World-renowned experts in neuroscience, bioengineering, and artificial intelligence.
Chief Scientific Officer
Former director of MIT's Neuroengineering Lab with 20+ years in neural interface development.
Chief Technology Officer
AI pioneer who led neural network research at DeepMind before joining NeuroSpectra.
Head of Organoid Research
Developed groundbreaking techniques for growing and maintaining functional neural organoids.
Stanford University, Computational Neuroscience
Author of "Neural Dynamics of Learning" and pioneer in spiking neural network theory.
Karolinska Institute, Neuropharmacology
Developed first organoid-based drug screening platform for neurological disorders.
ETH Zurich, Bioelectronic Interfaces
Inventor of the high-density microelectrode array used in modern BCIs.
Interested in NeuroSpectra Bridge for your research or institution? Get in touch with our team.
